I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Gulf War Illness Research Program

Therapeutic/Biomarker Trial Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-21-GWIRP-TBTA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Submission Deadline**: 5:00 p.m. Eastern time (ET), May 7, 2021
- **Invitation to Submit an Application**: June 2021
- **Application Submission Deadline**: 11:59 p.m. ET, August 19, 2021
- **End of Application Verification Period**: 5:00 p.m. ET, August 24, 2021
- **Peer Review**: October 2021
- **Programmatic Review**: December 2021

This program announcement must be read in conjunction with the General Application Instructions, version 601. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

## I. OVERVIEW OF THE FUNDING OPPORTUNITY

- II.A. Program Description ................................................................. 3
  - II.A.1. The Gulf War Illness Landscape ........................................... 3
  - II.A.2. FY21 GWIRP Overarching Challenges .................................. 3
  - II.A.3. Award History ...................................................................... 5
- II.B. Award Information .................................................................... 5
- II.C. Eligibility Information .............................................................. 12
  - II.C.1. Eligible Applicants ............................................................... 12
  - II.C.2. Cost Sharing .......................................................................... 13
  - II.C.3. Other ..................................................................................... 13
- II.D. Application and Submission Information ..................................... 13
  - II.D.1. Address to Request Application Package ................................. 14
  - II.D.2. Content and Form of the Application Submission ..................... 14
  - II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM) ............... 39
  - II.D.4. Submission Dates and Times .................................................. 39
  - II.D.5. Funding Restrictions .............................................................. 40
  - II.D.6. Other Submission Requirements ............................................. 42
- II.E. Application Review Information ................................................. 42
  - II.E.1. Criteria .................................................................................. 42
  - II.E.2. Application Review and Selection Process ............................... 48
  - II.E.3. Integrity and Performance Information ...................................... 48
  - II.E.4. Anticipated Announcement and Federal Award Dates ............... 49
- II.F. Federal Award Administration Information .................................. 49
  - II.F.1. Federal Award Notices ............................................................ 49
  - II.F.2. Administrative and National Policy Requirements ..................... 50
  - II.F.3. Reporting ............................................................................... 50
- II.G. Federal Awarding Agency Contacts ........................................... 51
  - II.G.1. CDMRP Help Desk ................................................................. 51
  - II.G.2. Grants.gov Contact Center ..................................................... 51
- II.H. Other Information ..................................................................... 52
  - II.H.1. Program Announcement and General Application Instructions Versions .......................................................... 52
  - II.H.2. Administrative Actions .......................................................... 52
  - II.H.3. Application Submission Checklist ........................................... 55

## APPENDIX 1: ACRONYM LIST ................................................................ 57
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP). The GWIRP was initiated in 2006 to provide support for research of exceptional scientific merit for studying effects of deployment to the 1990-1991 Persian Gulf War on U.S. Warfighters. Appropriations for the GWIRP from FY06 through FY20 totaled $214 million (M). The FY21 appropriation is $22M.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

II.A.1. The Gulf War Illness Landscape

The GWIRP has prepared an overview titled, “The Gulf War Illness Landscape,” which describes what is currently known about topics consistent with the mission of identifying treatments, improving definition and diagnosis, and understanding the pathobiology and symptoms of Gulf War Illness (GWI). Applicants are strongly encouraged to read and consider The Gulf War Illness Landscape before preparing their applications. The Landscape can be found at https://cdmrp.army.mil/gwirp/pdfs/GWIRP_Landscape_2020.pdf.

II.A.2. FY21 GWIRP Overarching Challenges

Considering the current Gulf War Illness Landscape and the GWIRP’s mission, all FY21 GWIRP applications must address at least one of the following overarching challenges unless adequate justification for exception is provided.

The TBTA supports clinical trials therefore all TBTA applications must address the FY21 GWIRP Overarching Challenge of “Treatments” as articulated below. Applications may also consider The Gulf War Illness Landscape and the GWIRP’s mission to address any of the other FY21 GWIRP Overarching Challenges or a different challenge identified and justified in the application in addition to the Treatments challenge.

- **Treatments:** Eliminate the health consequences associated with GWI and/or revolutionize treatment
- **Diagnosis:** Better define and diagnose GWI
- **Subtyping**: Distinguish subtypes to better target treatments, monitor therapy, identify severity of GWI, or to identify why GWI is worse for some Veterans than for others

- **Determinants**: Identify and validate determinants of GWI, including latency and impacts on organs and systems

- **Consequences**: Determine whether GWI alters risk for developing neurological conditions, cancers, or other serious conditions; or whether GWI alters outcomes of other infections/diseases

- **Communicate & Educate**: Help Veterans, their caregivers, and clinicians communicate effectively about GWI, its symptoms, and potential treatments

*With adequate justification, applications may identify and address another overarching challenge related to The Gulf War Illness Landscape. Justification must be provided in the application.*

To address the overarching challenges in a step-wise and translational manner, the FY21 GWIRP award mechanisms are aligned to the different phases of the research pipeline illustrated below.

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Qualification</th>
<th>Verification</th>
<th>Confirmation</th>
</tr>
</thead>
</table>
| • Innovative biomarker or treatment research  
• Earliest stages of development  
• High-risk/High-reward  
• No preliminary data required | • Preclinical expansion, replication, or comparative studies to validate preliminary or published data in GWI field  
• Preliminary data required | • Proof-of concept clinical translation of validated GWI findings  
• Large-scale biomarker research or early phase 1-2a intervention clinical trials  
• Strong preliminary data required | • Large-scale confirmatory and pivotal clinical trials to revolutionize GWI clinical care  
• Sufficiently-powered phase 2b-3 clinical trials  
• Objective biomarkers of effectiveness required |

The **Discovery phase** represents innovative biomarker or treatment research that is in the earliest stages of development. Applicants seeking support for research aligning to the Discovery phase should consider the **FY21 GWIRP Idea Award** (funding opportunity number W81XWH-21-GWIRP-IA) or the **FY21 New Investigator Award** (funding opportunity number W81XWH-21-GWIRP-NIA).

The **Qualification phase** represents preclinical research already supported by preliminary or published data in the GWI field that is ready for validation through expansion, replication, or comparative studies. Applicants seeking support for the Qualification phase should consider the **FY21 GWIRP Research Advancement Award** (funding opportunity number W81XWH-21-GWIRP-RAA) or the **FY21 New Investigator Award** (funding opportunity number W81XWH-21-GWIRP-NIA).
The Verification phase represents clinical translation of concepts previously validated through expansion, replication, or comparative studies. Examples of projects in the Verification phase include large-scale biomarker trials or phase 1 through 2a intervention trials. Applicants seeking support for the Verification phase should consider the FY21 GWIRP Clinical Evaluation Award (funding opportunity number W81XWH-21-GWIRP-CEA).

The Confirmation phase represents large-scale confirmatory and pivotal trials that will transform and revolutionize the clinical management of GWI. Sufficiently powered phase 2b through phase 3 clinical trials of previously piloted interventions will be supported. Objective biomarkers to measure the biological effect of an intervention or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual Gulf War Veteran or Gulf War Veteran subgroup are required. Applicants seeking support for the Confirmation phase should consider the FY21 GWIRP Therapeutic/Biomarker Trial Award (funding opportunity number W81XWH-21-GWIRP-TBTA).

**NOTE:** The scope of research proposed in applications in response to the FY21 GWIRP program announcements must align with the research phases outlined above. It is the responsibility of the applicant to select the award mechanism that aligns with the scope of the proposed research. The funding mechanism should be selected based on the research scope defined in the program announcement, and not on the amount of the budget. Applications submitted under a mechanism that is not deemed appropriate for the scope of research proposed will not be funded.

### II.A.3. Award History

The GWIRP Therapeutic/Biomarker Trial Award mechanism was first offered in FY19. Since then, four Therapeutic/Biomarker Trial Award applications have been received, and one has been recommended for funding.

### II.B. Award Information

The FY21 GWIRP Therapeutic/Biomarker Trial Award supports large-scale, pivotal (e.g., phase 2b-3) clinical trials that will revolutionize the clinical management of GWI. **The Therapeutic/Biomarker Trial Award targets the Confirmation phase of the research pipeline as outlined in Section II.A.2.** The proposed research should lead to an approach that is fundamentally better than interventions already approved or in clinical development. Objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual Gulf War Veteran or Gulf War Veteran subgroup must be included in the trial design.

Development of markers for the purposes of diagnosis, prognosis, or measurement of disease progression without consideration of the therapeutic development process will not be supported.

The FY21 GWIRP Therapeutic/Biomarker Trial Award supports clinical trials; therefore, all applications must address the FY21 GWIRP Overarching Challenge of “Treatments.” In addition, applicants may consider The Gulf War Illness Landscape and the GWIRP’s mission...
and address any of the other FY21 GWIRP Overarching Challenges or a different challenge identified and justified in the application.

Principal Investigators (PIs) are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully.

**Funding from this award mechanism must support a clinical trial.**

*A clinical trial is defined* as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded clinical trials are required to post a copy of the Institutional Review Board (IRB)-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in the Code of Federal Regulations, Title 32, Part 219 (2 CFR 219).

**Clinical research is defined** as: (1) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies; (2) epidemiologic and behavioral studies; and (3) outcomes research and health services research. Note: Studies that meet the requirements for IRB review Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.

Investigators seeking funding for a preclinical research project should consider one of the other FY21 GWIRP program announcements being offered.

For proposed research that will require U.S. Food and Drug Administration (FDA) involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines, proof of availability of and access to appropriate subject population(s), validated projections for patient recruitment, and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA that meets all requirements under 21 CFR 312. It is the responsibility of the applicant to provide evidence from the IRB of record or the FDA if an IND or IDE is not required.

If an IND is required, the IND application **must be submitted to the FDA by the FY21 GWIRP Therapeutic/Biomarker Trial Award application submission deadline.** The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND application) and indication to be tested in the proposed clinical trial. For more information on IND applications, the FDA has provided guidance at [https://www.fda.gov/drugs/developmentapprovalprocess/](https://www.fda.gov/drugs/developmentapprovalprocess/)
If an IDE is required, the IDE application must be submitted to the FDA by the FY21 GWIRP Therapeutic/Biomarker Trial Award application submission deadline. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.

Refer to Attachment 8, Regulatory Strategy, for additional details on documentation of FDA applications. The government reserves the right to withdraw funding if an IND or IDE application and/or international regulatory application is necessary but has not been submitted prior to the application submission deadline.

Biorepository Contribution Option: In FY17, the GWIRP awarded infrastructure support for a Gulf War Illness Biorepository. The Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI has now been established for the retention and distribution of Gulf War Veteran biospecimens and/or data related to GWI research. Applicants to the FY21 GWIRP are encouraged to contribute Gulf War Veteran biospecimens and data to this repository network. The FY21 GWIRP Therapeutic/Biomarker Trial Award offers a nested Biorepository Contribution Option with higher levels of funding for qualified applications as described in Section II.D.5, Funding Restrictions. See Attachment 13, Option Statements for additional submission requirements. Applicants interested in collaborating with this network should refer to the GWIRP Supported Initiatives on the GWIRP website.

Clinical Consortium Collaboration Option: In FY17, the GWIRP awarded a Clinical Consortium Award to create a network of institutions focused on designing and executing phase 1 and 2 clinical trials. The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) has now been established to investigate promising therapeutics for GWI. Applicants to the FY21 GWIRP are encouraged to make use of the established infrastructure of the GWICTIC, such as recruitment networks, existing protocols, Common Data Elements (CDEs), and data management procedures. Clinical Consortium Collaboration Option applications shall adhere to the GWICTIC policies and procedures with respect to biospecimens and data and therefore are not eligible to also submit under the Biorepository Contribution Option. A letter of collaboration from the GWICTIC is required, outlining the services that will be shared to bring value to the government. The FY21 GWIRP Therapeutic/Biomarker Trial Award offers a nested Clinical Consortium Collaboration Option with higher levels of funding for qualified applications as described in Section II.D.5, Funding Restrictions. See Attachment 13, Option Statements for additional submission requirements.

The following are important aspects of the GWIRP Therapeutic/Biomarker Trial Award, in addition to the items outlined above:

- **Preliminary Data:** Inclusion of preliminary data from the field of GWI relevant to the proposed clinical trial is required.

- **Start Time:** The proposed clinical trial is expected to begin no later than 12 months after the award date, or 18 months after the award date for FDA-regulated studies.
**Recruitment Plan and Milestones:** The application must include a sound subject recruitment and retention plan and demonstrate availability of and access to a suitable Gulf War Veteran population that will support a meaningful, statistically significant outcome for the study. A resource containing guidance for successful access to Gulf War Veterans titled, “General Guidance for Gulf War Veteran Subject Outreach and Recruitment,” can be found on the GWIRP webpage at [https://cdmrp.army.mil/gwirp/pdfs/General%20_Guidance_for_Gulf_War_Veteran_Outreach_and_Recruitment.pdf](https://cdmrp.army.mil/gwirp/pdfs/General%20_Guidance_for_Gulf_War_Veteran_Outreach_and_Recruitment.pdf). Successful applicants will work with USAMRAA to establish milestones for human subject recruitment. Continued support for the project will be based upon satisfactory progress in meeting the established milestones.

**Therapeutic Access:** The application should demonstrate availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. The quality and stability of the product should be documented and commensurate with current FDA manufacturing standards applicable to the type and phase of product being developed (i.e., Quality System Regulation, Good Manufacturing Practice [GMP] guidelines).

**FDA Experience:** If applicable, the application should demonstrate experience on the study team in interacting with the FDA, including previous FDA submissions.

**Statistical Analysis Plan:** The application should include a clearly articulated statistical analysis plan, demonstrate appropriate statistical expertise on the research team, and include a power analysis reflecting sample size projections that will answer the objectives of the study.

**Safety Management Plan:** The application should include a clearly articulated safety management plan outlining how safety pharmacovigilance will be conducted, as applicable.

**Clinical Monitoring Plan:** The application should include a clearly articulated clinical monitoring plan outlining how the study will be monitored for Good Clinical Practice (GCP) compliance.

**Data Management Plan:** The application should include a clearly articulated data management plan and use of an appropriate database to safeguard and maintain the integrity of the data. If FDA-regulated, the trial must use a 21 CFR 11-compliant database and appropriate data standards. For more on data standards, see [https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM511237.pdf](https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM511237.pdf).

**Study Coordinator:** The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.

**Transition Plan:** The application should include a Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical trial phase and/or delivery to Veterans suffering from GWI after the successful completion of the FY21 GWIRP Therapeutic/Biomarker Trial Award.
• **Institutional Support:** The application should clearly demonstrate strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled.

• **NIH Clinical Trials.gov Registration:** Funded clinical trials are required to register the study in the National Institutes of Health (NIH) clinical trials registry, [https://www.clinicaltrials.gov/](https://www.clinicaltrials.gov/), prior to initiation of the study. Refer to the General Application Instructions, Appendix 1, Section C, for further details.

• **Costs/Budget:** The requested budget must be commensurate with the phase and size of the trial proposed.

**Activities not supported under this program announcement include:**

• Studies focusing on psychiatric disease or psychological stress as the primary cause of GWI or implementation of care guidelines placing significant emphasis on psychiatric pathologies or psychiatric remedies.

• Applications focusing on amyotrophic lateral sclerosis (ALS) research. However, applications that focus on GWI symptomatology may include Gulf War Veterans with ALS if the latter disorder is included in the study’s GWI case definition. For those interested in pursuing ALS-focused studies, the CDMRP offers funding opportunities through the ALS Research Program (see [https://cdmrp.army.mil/alsrp](https://cdmrp.army.mil/alsrp)).

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated direct costs budgeted for the entire period of performance for an FY21 GWIRP TBTA award will not exceed $5,000,000. If applying under the Biorepository Contribution Option, direct costs will not exceed $5,020,000. If applying under the Clinical Consortium Collaboration Option, direct costs will not exceed $5,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2022. For additional information refer to Section II.F.1, Federal Award Notices.
The CDMRP expects to allot approximately $8.0M to fund approximately one Therapeutic/Biomarker Trial Award application. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Development Command (USAMRDC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the IRB or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.

If the proposed research is cooperative (i.e., involving more than one institution), plans for the multi-institutional structure governing the research protocol(s) should be outlined.

A written plan for single IRB review arrangements must be provided for cooperative research conducted in the United States. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements. The master protocol and consent form must be reviewed by the Human Research Protection Office (HRPO) prior to distribution to the additional sites for IRB/EC review. Communication and data transfer between or among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials.

Access to Veterans of the 1990-1991 Gulf War: Applicants not collaborating with the GWICTIC are encouraged to collaborate with an investigator who has demonstrated access to Gulf War Veterans, particularly investigators within the Department of Veterans Affairs (VA) or other GWIRP-supported investigators, to ensure access to Gulf War Veteran populations as applicable to the proposed project. Applicants interested in leveraging existing cohorts recruited in other GWIRP-supported studies can refer to the Research Resources link (https://cdmrp.army.mil/gwirp/resources/gwirpresources) on the GWIRP website. Access to Gulf War patient populations should be confirmed at the time of application submission. A letter of support, signed by the lowest-ranking person with approval authority, should be included for studies involving active-duty military, Veterans, military and/or VA-controlled study materials, and military and/or VA databases.
Use of DOD or VA Resources: If the proposed research involves access to active-duty military patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

Gulf War Veteran Recruitment: Applicants not collaborating with the GWICTIC are strongly encouraged to consider the outreach and recruitment best practices described online at https://cdmrp.army.mil/gwirp/pdfs/General%20_Guidance_for_Gulf_War_Veteran_Outreach_and_Recruitment.pdf.

GWI Case Definitions for Clinical Research: In 2014 the Institute of Medicine (IOM) (now called National Academy of Medicine) released a report, “Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined” (available online at http://www.nationalacademies.org/hmd/Reports/2014/Chronic-Multisymptom-Illness-in-Gulf-War-Veterans-Case-Definitions-Reexamined.aspx). In this report, the IOM recommended the use of both the U.S. Centers for Disease Control and Prevention’s (CDC) definition of GWI and the “Kansas” definition of GWI. Applicants proposing clinical research may construct a definition of subgroups or symptom clusters as appropriate to the specific research; however, all cases and controls must additionally be scored and analyzed according to both the CDC and the Kansas definitions of GWI for comparative purposes. Any additional project-specific case definition must recognize the multisymptom nature of GWI. Another resource for clinical investigations includes the 2014 report of the Research Advisory Committee on Gulf War Veterans’ Illnesses, “Gulf War Illness and the Health of Gulf War Veterans: Research Update and Recommendations, 2009-2013,” which provides information on GWI, including case definitions and research on epidemiology, etiology, pathobiology, and treatment. This report can be found online at https://www.va.gov/RAC-GWVI/RACReport2014Final.pdf.

CDEs for Clinical Research: Through a collaboration between the NIH, CDC, VA, DOD GWIRP, and the GWI community, CDE recommendations are being developed for GWI. The goals of this effort are to increase the efficiency and effectiveness of clinical research studies and treatment, increase data quality, facilitate data sharing and aggregation of information across studies, and help educate new clinical investigators. In early 2018, members from the GWI community participated in a CDE development working group to prepare standard template case report forms and instrument recommendations for clinical research studies. The version 1.0 recommendations were posted on the GWIRP website at https://cdmrp.army.mil/gwirp/default in January 2019. The GWIRP strongly encourages applicants in the clinical research community, whether or not collaborating with the GWICTIC, to read and consider the CDEs, which are used by GWICTIC, when preparing applications. Use of CDEs is expected to expedite study start-up, standardize data collection, and allow for future data sharing. CDEs will be required in clinical research going forward and must be considered by investigators submitting samples to the BBRAIN under the Biorepository Contribution Option. It should be noted that the development of CDEs is an iterative process. Updates will be made to the GWI CDEs as research progresses and feedback is received from the community.
Rigor of Experimental Design: All projects should adhere to standards for rigorous study design and reporting to maximize the reproducibility and translational potential of the research. Policies and resources that should be consulted to enhance reproducibility include:

- “Enhancing Reproducibility through Rigor and Transparency” policy, developed by NIH, to clarify expectations for grantees and reviewers in describing or assessing proposed studies in applications and progress reports, announced in 2015 and implemented in 2016. For more information, see https://grants.nih.gov/policy/reproducibility/index.htm.

- The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommends an evidence-based minimum set of reporting elements for systematic reviews and meta-analyses; was developed by an international group; and was first published in 2009 in multiple journals (PLOS Medicine, Annals of Internal Medicine, BMJ, Journal of Clinical Epidemiology, and Open Medicine) and was updated in 2015. For more information, see http://www.prisma-statement.org/.

- The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, developed by an international collaboration of trialists, methodologists, journal editors, and ethicists, recommends minimum content to include in clinical trial protocols, from study enrollment through closeout, first published in the Annals of Internal Medicine and BMJ in 2013. For more information, see https://www.spirit-statement.org.

- BEST (Biomarkers, EndpointS, and other Tools) Resource is an online glossary developed by a Food and Drug Administration and NIH joint committee to clarify terms used in translational science and medical product development, with a focus on study endpoints and biomarkers. For information, see https://www.ncbi.nlm.nih.gov/books/NBK326791/.

- ClinRegs is a public website developed by NIH’s National Institute of Allergy and Infectious Diseases to help researchers navigate country-specific regulatory information as they plan and implement clinical trials. For information, see https://clinregs.niaid.nih.gov/.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.
Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organization other than the DOD, and research institutes.

Intramural DOD Organization: A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. Intramural Submission: Application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.

USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

Independent investigators at any academic level (or equivalent) may be named by the organization as the PI on the application.

There are no limitations on the number of applications for which an investigator may be named as a PI.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at https://orcid.org/.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).
Extramural Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DOD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.

II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1, Full Application Guidelines).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type will delay processing.
If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The applicant organization and associated PI identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

When starting the pre-application, PIs should ensure that they have selected the appropriate application category:

- Therapeutic/Biomarker Trial Award (TBTA)
- Therapeutic/Biomarker Trial Award - Biorepository Contribution Option (TBTA-BCO)
- Therapeutic/Biomarker Trial Award - Clinical Consortium Collaboration Option (TBTA-CCCO)

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**
  
  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**
  
  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds
to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

**FY21 GWIRP Programmatic Panel members** should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

*Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

- **Prepropositional Narrative (three-page limit):** The Prepropositional Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Prepropositional Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  - Explain how the pre-application proposes research that will lead to a solution for the [FY21 GWIRP Overarching Challenge](#) of eliminating the health consequences associated with GWI and/or revolutionizing treatment.

  - Describe how the scope of the proposed research is appropriate for the Confirmation phase and is advancing a treatment approach that is fundamentally better than interventions already approved or in clinical development.

  - Describe the clinical intervention and phase of the clinical trial proposed. Describe a plan for project readiness by the application deadline with respect to availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines, availability of and access to appropriate subject population(s), and submission of an IND or IDE application to the FDA, if applicable.
– Describe use of a biomarker(s) to measure biological effect of the intervention or predictive/cohort-selective biomarkers to indicate whether a specific therapy will be effective in a Gulf War Veteran subgroup.

○ **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application *must be uploaded as individual files* and are limited to the following:

  – References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).

  – List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

  – Key Personnel Biographical Sketches (five-page limit per individual). *All biographical sketches should be uploaded as a single combined file.* Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- **Tab 6 – Submit Pre-Application**

  This tab must be completed for the pre-application to be accepted and processed.

**Pre-Application Screening**

- **Pre-Application Screening Criteria**

  To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the GWIRP, pre-applications will be screened based on the following criteria:

  ○ To what degree the pre-application proposes research that will lead to a solution for the [FY21 GWIRP Overarching Challenge](#) of eliminating the health consequences associated with GWI and/or revolutionizing treatment.

  ○ To what degree the research scope described in the pre-application is appropriate for the Confirmation phase of the research pipeline.

  ○ To what degree the proposed research has the potential to lead to a treatment approach that is fundamentally better than interventions already approved or in clinical development.

  ○ Whether the pre-application describes a feasible plan for project readiness by the application submission deadline.

  ○ Whether use of a biomarker(s) to measure biological effect of the intervention or predictive/cohort-selective biomarkers are described.
• Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in Section I, Overview of the Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

II.D.2.b. Step 2: Full Application Submission Content

Applications will not be accepted unless notification of invitation has been received.

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader must be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the same version of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

*Do not password protect any files of the application package, including the Project Narrative.*
### Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DOD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td><strong>Download application package components for W81XWH-21-GWIRP-TBTA from Grants.gov (<a href="https://www.grants.gov">https://www.grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</strong></td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative. <strong>Tab 3 – Full Application Files:</strong> Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
<tr>
<td><strong>SF424 Research &amp; Related Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 4 – Application and Budget Data:</strong> Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form. <strong>Tabs 3 – Full Application Files:</strong> Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
</tbody>
</table>
| Descriptions of each required file can be found under Full Application Submission Components: | • **Attachments**  
• **Research & Related Personal Data**  
• **Research & Related Senior/Key Person Profile (Expanded)**  
• **Research & Related Budget**  
• **Project/Performance Site Location(s) Form**  
• **Research & Related Subaward Budget Attachment(s) Form** | | |
| | | | |
## Application Package Submission

**Extramural Submissions**

Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.

Submit a Grants.gov Workspace Package. An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package **at least 24-48 hours prior to the close date** to allow time to correct any potential technical issues that may disrupt the application submission.

**Note:** If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID **prior to** the application submission deadline. **Do not password protect any files of the application package, including the Project Narrative.**

**Intramural DOD Submissions**

Submit package components to eBRAP ([https://ebrap.org](https://ebrap.org)).

Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email. **Do not password protect any files of the application package, including the Project Narrative.**

## Application Verification Period

The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified **with the exception of the Project Narrative and Research & Related Budget Form.**

After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified **with the exception of the Project Narrative and Research & Related Budget Form.** Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.
Extramural Submissions | Intramural DOD Submissions
---|---
**Further Information**

**Tracking a Grants.gov Workspace Package.**
After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.

Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

- **Extramural Applications Only**

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.
Outline for Project Narrative: Describe the proposed project in detail using the outline below.

- **Background:** Describe in detail the scientific rationale for the study. Include preliminary data collected from relevant previous pilot trials in GWI Veterans or populations with conditions related to GWI and describe how the proposed study validates or confirms findings. Describe the strengths and weaknesses in the rigor of the prior research (both published and unpublished) that serves as the key support for the proposed project. Describe plans to address weaknesses in the rigor of the prior research. If the intervention is used for another condition, include a rationale explaining why the proposed intervention would be expected to be effective for GWI and present preliminary data from the field of GWI that provides a pathological rationale for use of the treatment in a large-scale trial of GWI Veterans.

- **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses. This information should agree with the primary aims and associated tasks described in the Statement of Work (SOW) (Attachment 4).

- **Research Strategy and Feasibility:** Outline the proposed methodology in sufficient detail to show a clear course of action.
  - Identify the intervention to be tested and describe the targeted outcomes.
  - Describe the stage of trial (phase 2b through phase 3) and the study model (e.g., single group, parallel, crossover). Define each arm/study group of the proposed trial, if applicable.
  - Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures). Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).
  - Outline whether subjects, clinicians, data analysts, and/or others will be blinded during the study. Describe any other measures to be taken to reduce bias.
  - Describe objective biomarkers to be used as clinical endpoints. Biomarkers may originate from the investigator’s laboratory or be derived from previously published markers in the context of GWI. Valid biomarker endpoints include a measure of the biological effect of a therapeutic or evidence of a Gulf War Veteran subgroup that will benefit from the proposed intervention.
  - Define other primary, secondary, or interim endpoints/outcome measures, outline why they were chosen, and describe how and when they will be measured. Applicants are encouraged to include multiple endpoints from varied domains as appropriate. Include a description of appropriate controls.
Briefly describe the inclusion and exclusion criteria that will be used and describe the methods that will be used to recruit Gulf War Veterans. A full description of the recruitment plan should be detailed in Attachment 6, Human Subject Recruitment and Safety Procedures. All subjects and controls must be scored at least according to both CDC and Kansas case definitions for GWI for the purpose of comparative analysis. If an additional case definition other than the CDC or Kansas definition is to be used, describe this definition and how it is quantified, and explain the rationale behind its inception and use.

Describe potential problem areas and discuss alternative methods/approaches that may be employed to overcome them.

- **Statistical Model and Data Analysis Plan:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the research team member(s) responsible for statistical and data analysis. Specify and justify the rationale for the approximate number of human subjects to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study. Ensure sufficient information is provided to allow thorough evaluation of all planned statistical procedures during review of the application.

- **Attachment 2: Supporting Documentation:** Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate
whether or not government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- Letters of Organizational Support: Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

- Letters of Commitment (if applicable): If the proposed study involves use of a commercially produced investigational drug, device, or biologic, provide a letter of commitment from the commercial entity indicating availability of the product/therapeutic for the duration of the study, support for the proposed phase of research, and support for the indication to be tested.

- Intellectual Property: Information can be found in 2 CFR 200.315, “Intangible Property.”

  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

- Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.

- Access to Veterans of the 1990-1991 Gulf War (if applicable): Provide a letter of support from a VA or GWIRP-supported investigator(s) confirming access to Gulf War Veteran populations. The letter should be signed by the lowest ranking person with approval authority and should be included for studies involving active-duty military, Veterans, military and/or VA-controlled study materials, and military and/or VA databases.
Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Inclusion Plan: Provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at https://ebrap.org/eBRAP/public/Program.htm


Technical Abstract (one-page limit). The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. The programmatic reviewers may not have access to the full application and may rely on the technical abstract for appropriate description of the project’s key aspects. Therefore, clarity and completeness within the space limits of the technical abstract are highly important.

- Overarching Challenge(s): Explain how the proposed research will lead to a solution for the FY21 GWIRP Overarching Challenge of eliminating the health consequences associated with GWI and/or revolutionizing treatment.
- Background: Present the ideas and rationale behind the proposed clinical trial.
- Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached.
- Specific Aims: State the specific aims of the study.
- Study Design: Briefly describe the study design, including appropriate controls.
- Clinical Impact: Briefly describe how the proposed project will transform and revolutionize the clinical management of GWI.

Lay Abstract (one-page limit). The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Do not duplicate the technical abstract. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. The lay abstract is an
important component of the application review process because it addresses issues of particular interest to the consumer advocate community.

- **Overarching Challenge:** Explain how the proposed research will lead to a solution for the FY21 GWIRP Overarching Challenge of eliminating the health consequences associated with GWI and/or revolutionizing treatment.

- **Objective and Rationale:** Describe the scientific objective and rationale for the proposed study and intervention in a manner readily understood by readers without scientific or medical backgrounds.

- **Applicability and Impact:** Describe the ultimate applicability and impact of the research.
  - What are the clinical applications, benefits, and risks for Veterans with GWI?
  - What is the projected time it may take to achieve a patient-related outcome?

- **Attachment 4: Statement of Work (six-page limit):** Upload as “SOW.pdf”. The suggested (SOW) format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). Recommended strategies for assembling the SOW can be found at https://ebrap.org/eBRAP/public/Program.htm.

For the Therapeutic/Biomarker Trial Award mechanism, refer to the “Suggested SOW Strategy Clinical Research” document for guidance on preparing the SOW and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

- **Attachment 5: Intervention (no page limit):** Upload as “Intervention.pdf”. The Intervention attachment should include the components listed below.
  - **Description of the Intervention:** Identify the intervention to be tested. As applicable, the description of the intervention should include the following components: complete name and composition, storage and handling information, source, dose, schedule, administration route, washout period, duration of the intervention, and concomitant medications allowed. Description of devices should include general concept of design, detailed operational instructions, any potential risks to users, and intended benefits. Other types of interventions should be fully described. Indicate who holds the intellectual property rights to the intervention, if applicable, and how the PI has obtained access to those rights for conduct of the clinical trial.
  - Summarize key preclinical pharmacological findings, dosage studies, and other clinical studies that examine the safety and stability (as appropriate) of the intervention.
Study Procedures: Describe the interaction with the human subject, including the study intervention that he/she will experience. Provide sufficient detail in chronological order for a person uninvolved in the study to understand what the human subject will experience. Provide a schedule (e.g., flowchart or diagram) of study evaluations and follow-up procedures. Clearly delineate research procedures from routine clinical procedures. Discuss how compliance with current Good Laboratory Practice (GLP) guidelines, GMP, and other regulatory considerations will be established, monitored, and maintained, as applicable.

Clinical Monitoring Plan: Describe how the study will be conducted by and monitored for current ICH E6 (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) GCP compliance, by an independent clinical trial monitor (or clinical research associate). The monitoring plan should describe the types of monitoring visits to be conducted, the intervals (based on level of risk), how corrective actions will be reported to the Sponsor and PI, and how they will be corrected and prevented by the clinical trial site/PI.

Attachment 6: Human Subject Recruitment and Safety Procedures (no page limit): Upload as “HumSubProc.pdf”. The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.

- Study Population: Describe the nature, approximate number, and pertinent demographic characteristics of the target 1990-1991 Gulf War Veteran population. Include information about specific symptom profiles relevant to GWI and the proposed clinical trial.

- Inclusion/Exclusion Criteria: List the inclusion and exclusion criteria for the proposed clinical trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender.

- **Inclusion of Women and Minorities in Study.** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the clinical trial.

- Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, racial, and ethnic group, and an accompanying rationale for the selection of subjects.
Gulf War Veteran Outreach and Recruitment Plan: Outreach and positive recruitment and retention have historically been an issue in the study of Gulf War Veterans. Recruiting and retaining participants requires careful consideration. Outreach and recruitment activities need to be identified early in the planning process and should include the involvement of appropriate sources within the community and considerations for Veteran subject compensation. The Gulf War Veteran Outreach and Recruitment Plan must include the components listed below. A resource containing additional guidance for successful access to Gulf War Veterans titled, “General Guidance for Gulf War Veteran Subject Outreach and Recruitment,” can be found on the GWIRP webpage at https://cdmrp.army.mil/gwirp/pdfs/General%20_Guidance_for_Gulf_War_Veteran_Outreach_and_Recruitment.pdf.

Describe the activities that will be used to identify and recruit potential subjects using the outline below. All advertisements and recruitment materials must be approved by the respective IRB/EC prior to use. Local IRB/EC approval at the time of application submission is not required.

- **Specific Approaches:** Summarize the outreach and recruitment plan in detail including drawing on an existing cohort, partnering with an established GWI researcher, advertising, appearances at events, direct mail, and other approaches. Provide a table of anticipated enrollment counts at each study site.

- **Organizations:** Name the specific organizations that will participate in recruitment efforts.

- **Staff:** Describe the composition and duties of the outreach/recruiting staff. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable). Describe training they will receive for interacting with and recruiting Veterans.

- **Recruitment Materials:** The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study. Encouraging themes describing how the research might benefit fellow Gulf War Veterans or Veterans of later deployments suffering from similar exposures are acceptable. Describe electronic, paper, or other recruitment materials to be employed.

- **Compensation and Incentives:** Include a description of the compensation plan for travel, meals, lodging, participation incentives, and any other compensation or incentives.

- **Physical and Logistical Accommodation of Subjects:** Describe measures that will be taken at the trial facility to accommodate subjects including aid in reaching the facility, moving or navigation within the facility, and assignment of and access to staff points of contact for inquiries or requests for assistance.
- Alternate Approaches: Address any potential barriers to accrual or other potential unanticipated delays. Include detailed plans for alternate approaches to be employed if recruitment lags behind schedule. Include a mitigation plan for slow or low enrollment. Identify ongoing clinical trials that may compete for the same patient population and how they may impact enrollment progress.

- Sharing of Study Results: Describe plans for dissemination of study results to participants including:
  - Aggregate, final study results including any lay-oriented materials other than scientific publications.
  - Individual study test results for individual subjects.

- Description of the Informed Consent Process: Specifically describe the plan for obtaining informed consent from human subjects.
  - For the proposed study, provide a draft, in English, of the Informed Consent Form.
  - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the trial.
  - Include information regarding the timing and location of the consent process.
  - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
  - Address how privacy and time for decision-making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
  - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.
  - Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: In compliance with 10 USC 980 (https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf), the application must own consent to participate in the proposed clinical trial. If applicable, refer to the General Application Instructions, Appendix 1, for more information.
- **Assent.** If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Note: Some screening procedures may require a separate consent or a two-stage consent process.

- **Risks/Benefits Assessment:**
  - **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical trial. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

- **Risk management and emergency response:**
  - Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
  - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
  - Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
  - Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
  - Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
  - If the IRB determines that a trial presents greater than minimal risk to human subjects, the DOD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, refer to the General Application Instructions,
Appendix 1, Section B (Research Monitor Requirement), for more information on study reporting authorities and responsibilities of the research monitor.

- **Potential benefits:** Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.

  - **Attachment 7: Data Management (no page limit):** Upload as “Data_Manage.pdf”. The Data Management attachment should include the components listed below.
    - **Data Management:** Describe all methods used for data collection and their feasibility, including the following:
      - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
      - **Confidentiality:**
        - Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
        - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DOD are eligible to review study records.
        - Address requirements for reporting sensitive information to state or local authorities.
      - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.
      - **GWI CDEs:** Describe how the use of the newly established GWI CDEs will be incorporated into the collection of clinical data and annotation of clinical describe a clear intent to benefit for human subjects who cannot give their samples.
• **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

• **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  – **Laboratory Evaluations:**

    • **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

    • **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

    • **Storage:** Describe specimen storage, including location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use, including considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

    • **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, the applicable quality standard, and any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

  o **Attachment 8: Regulatory Strategy (no page limit):** If submitting multiple documents, start each document on a new page. Combine and upload as a single file named “Regulatory.pdf”. Answer the following questions and provide supporting documentation as applicable.

    – State the product/intervention name.

    **For products/interventions that do not require regulation by the FDA:**

    – Explain why the product/intervention is exempt from FDA oversight. Provide confirmation that the trial does not require regulation by the FDA in writing from the IRB of record or the FDA. No further information for this Attachment is required.
For products/interventions that require regulation by the FDA:

- State whether the product is FDA-approved, -licensed, or -cleared, and marketed in the U.S.

- If the product is marketed in the U.S., state the product label indication. State whether the proposed research involves a change to the approved label indication for the route of administration, dosage level, and/or subject population. Indicate whether the proposed research involves a change that increases the risks associated with using the product. State whether the product is being promoted for an off-label use (where promotion involves the sale of a marketed product).

- If the product is not currently FDA-approved, -licensed, or -cleared, state the planned indication/use. Indicate whether the product would be classified as a drug, device, biologic, or combination product. Indicate whether the FDA has confirmed the proposed classification. Identify the regulatory sponsor. Include a signed sponsor commitment letter acknowledging the regulatory sponsor’s understanding of all sponsor responsibilities and commitment to oversee execution of the study.

For the FY21 GWIRP Therapeutic/Biomarker Trial Award, if an IND or IDE is required, the application must be submitted to the FDA prior to the FY21 GWIRP Therapeutic/Biomarker Trial Award application submission deadline. The IND or IDE should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and indication to be tested in the proposed clinical trial. Provide the date of submission, the application number, and a copy of the FDA letter acknowledging the submission. If there are any existing cross-references in place, provide the application number(s) and associated sponsor(s). Provide an explanation of the status of the application (e.g., past the critical 30-day period, pending response to questions raised by the FDA, on clinical hold, on partial clinical hold, etc.). If the IND or IDE application has been placed on clinical hold or partial hold, explain the conditions that must be met for release of the hold. Provide a summary of any previous meetings with the FDA on development of this product. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.

- If available, provide a copy of the communication from the FDA indicating the IND or IDE application is active/safe to proceed.

- If an active IND or IDE for the investigational product is in effect, but an amendment is needed to include the proposed trial, describe the type and nature of the amendment(s) and the timeline for submission. Indicate whether the amendment increases the risk of the intervention.

- Provide the current status for manufacturing development (e.g., manufacturer’s name, GMP-compliant lots available, status of stability testing, etc.), non-clinical development (e.g., test facility name, status of pivotal GLP toxicology studies to
support phase 1 testing, etc.), and clinical development (e.g., clinical site name, safety profile, status of any completed or ongoing clinical trials).

- Describe the overall regulatory strategy and product development plan that will support the planned product indication. Include a description of the numbers and types of studies proposed to reach approval, licensure, or clearance, the types of FDA meetings that will be held/planned, and the submission filing strategy. Include considerations for compliance with current GMP, GLP, and GCP guidelines.

o Attachment 9: Study Personnel and Organization (no page limit): Start each document on a new page. Combine into one document and upload as “Personnel.pdf”. The Study Personnel and Organization attachment should include the components listed below.

- Organizational Chart: Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers, and/or departments and name each person’s position on the project. Include any separate laboratory or testing centers. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, as appropriate. Identify and provide justification for the inclusion of international sites, as appropriate. If applicable, identify the FDA regulatory sponsor and any external consultants or other experts who will assist with FDA applications. While there is no specified format for this information, a table(s) or diagram is recommended. Note: This item may be made available for programmatic review.

- Study Personnel Description: Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role, including previous interactions with the FDA, if applicable. An external research monitor (if applicable) and study coordinator(s) should be included.

- Study Management Plan: Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical trial is multi-institutional, clearly describe the multi-institutional structure governing the research protocol(s) across all participating institutions. Provide a regulatory submission plan for the master protocol and master consent form by the lead organization; include a single IRB/EC pathway whenever possible. If applicable, describe how communication and data transfer between the collaborating institutions will occur, as well as how data, specimens, and/or imaging products obtained during the study will be handled and shared.

o Attachment 10: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit): Upload as “Surveys.pdf”. The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information
collected is related to the objectives of the study. Describe how and when the instrument(s) will be administered. Describe how the instrument(s) will be adapted to the subject population, if applicable.

- **Attachment 11: Transition Plan (three-page limit): Upload as “Transition.pdf”**. Describe/discuss the methods and strategies proposed to move the intervention to the next phase of development (clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below.

  - Details of the funding strategy that will be used to bring the outcomes to the next level of development or delivery to Veterans with GWI (e.g., specific potential industry partners, specific funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.

  - A brief schedule and milestones for transitioning the intervention to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the FDA).

  - Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government’s ability to access such products or technologies in the future.

  - A risk analysis for cost, schedule, manufacturability, and sustainability.


  - Describe how the project will address the FY21 GWIRP Overarching Challenge of eliminating the health consequences associated with GWI and/or revolutionizing treatment.

  - If the project addresses another FY21 GWIRP Overarching Challenge(s), summarize how the project will address the challenge. If the project addresses an additional applicant-defined overarching challenge, provide justification within the context of The Gulf War Illness Landscape.

  - Identify the Gulf War Veteran population(s) that will participate in the proposed clinical trial, describe how they represent the target population that would benefit from the proposed intervention, and describe the potential impact of the proposed clinical trial on the outcomes of Veterans with GWI.
- **Describe the short-term impact:** Detail the anticipated outcomes that will be directly attributed to the results of the proposed clinical trial and describe anticipated short-term benefits for individuals.

- **Describe the long-term impact:** Explain the long-range vision for implementation of the intervention in the clinic. Describe how the intervention or therapeutic will improve patient care and/or quality of life of Veterans with GWI.

- Describe any relevant controversies or treatment issues that will be addressed by the proposed clinical trial.

- Describe any potential issues that might limit the impact of the proposed clinical trial.

- Describe how the intervention represents an approach that is fundamentally better than interventions already approved or in clinical development.

- **Attachment 13: Option Statements (three-page limit):** Upload as “Options.pdf”. *(Required for applications submitted under the Biorepository Contribution Option OR the Clinical Consortium Collaboration Option. Clinical Consortium Collaboration Option applications will adhere to the GWICTIC policies and procedures with respect to biospecimens and data and may not submit a separate Biorepository Contribution Statement.)* If the applicant is not applying to the Biorepository Contribution Option or the Clinical Consortium Collaboration Option, leave Attachment 13 blank.

- **Biorepository Contribution Statement:** Describe the types of datasets and/or biospecimens to be contributed to the BBRAIN, giving the approximate number of each. Provide a detailed accounting of proposed costs (per-sample basis as well as in aggregate). Describe any special preparation required and the facilities and technical capabilities necessary for collection, storage, and transfer of data and/or specimens. Describe plans for adhering to the standard operating procedures (SOPs), quality assurance measures, and annotation standards for clinical and pathological specimens and data established by the BBRAIN members. Clearly explain how the applicant plans to coordinate with the BBRAIN and provide a plan for resolving any intellectual and material property issues related to contribution of samples and/or data. State whether clinical data will be associated with samples or research datasets and, if applicable, describe how patient data confidentiality will be maintained in compliance with federal and state regulations. Contributing sites must ensure IRB approval and informed consent to share samples and data.

- **Clinical Consortium Collaboration Statement:** The GWICTIC currently consists of five Clinical Research Sites and one Coordinating Center. The Coordinating Center, in addition to functioning as a Clinical Research Site, serves as the Consortium information and planning nexus providing administrative, operational, and data management support services to participating Clinical Research Sites to implement clinical trials in a timely manner. Institutions collaborating with the GWICTIC will leverage capabilities and integrate SOPs, quality assurance measures, CDEs, and data management procedures into the project. The application should
clearly articulate the qualifications of the research team and institution to participate as a new Clinical Research Site in the Consortium. **A Letter of Collaboration is required for applications submitted under the Clinical Consortium Collaboration Option to demonstrate engagement of the GWICTIC.** Provide this letter as part of the Clinical Consortium Collaboration Statement.

Provide evidence that the research team and institution fulfill each of the following criteria for participation in the Consortium:

- Describe the PI’s experience in conducting multi-institutional clinical trials that demonstrate willingness and ability to participate in collaborative clinical trials and function in the Consortium.

- Include a named institutional Clinical Research Coordinator who will interact with the Supervising Clinical Research Coordinator at the Coordinating Center to guide clinical protocols through the regulatory approval processes, coordinate participant accrual, and coordinate study activities across sites.

- Clearly explain how intellectual and material property issues related to contribution of samples and/or data will be resolved.

Provide an accounting of proposed costs, including but not limited to costs for personnel integral to collaboration, data and sample sharing and storage expenses, quality assurance considerations, and data management considerations.

- **Attachment 14:** Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

- **Attachment 15:** Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

**Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681(a) et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in
science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

**Research & Related Personal Data:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

  For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.

  For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

- Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf”.

- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

**Research & Related Budget:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

**Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

**Project/Performance Site Location(s) Form:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.
• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

○ Intramural DOD Collaborator(s): Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 15. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the federal awarding agency is ready to make a federal award, the federal awarding agency may determine that the applicant is not qualified to receive a federal award and use that determination as a basis for making a federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI): Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Application Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the
organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

**Extramural Submission:** The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

**Intramural DOD Submission:** After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

**For All Submissions:** Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

**II.D.5. Funding Restrictions**

The maximum period of performance is 3 years.

The anticipated direct costs budgeted for the entire period of performance will not exceed $5,000,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the government exceeding $5,000,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

**Application to the Therapeutic/Biomarker Trial Award with the Biorepository Contribution Option:** If applying for the Biorepository Contribution Option, PIs may
include additional direct costs up to $20,000 associated with the contribution of samples and data to the BBRAIN.

- The anticipated direct costs budgeted for the entire period of performance will not exceed $5,020,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the government exceeding $5,020,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

- A Therapeutic/Biomarker Trial Award application including the Biorepository Contribution Option that does not meet the criteria specified may be funded at the lower maximum direct costs of $5,000,000 (i.e., at the level of the standard Therapeutic/Biomarker Treatment Award) as described above.

Application to the Therapeutic/Biomarker Trial Award with the Clinical Consortium Collaboration Option: If applying for the Clinical Consortium Collaboration Option, PIs may include additional direct costs up to $500,000 associated with collaborative activities involving participation of the GWICTIC. Clinical Consortium Collaboration Option applications shall adhere to the GWICTIC policies and procedures with respect to biospecimens and data and therefore are not eligible to also submit under the Biorepository Contribution Option.

- The anticipated direct costs budgeted for the entire period of performance will not exceed $5,500,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the government exceeding $5,500,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

- A Therapeutic/Biomarker Trial Award application including the Clinical Consortium Collaboration Option that does not meet the criteria specified may be funded at the lower maximum direct costs of $5,000,000 (i.e., at the level of the standard Therapeutic/Biomarker Trial Award) as described above.

Milestone Meetings: Research milestones to be accomplished by the end of each year in the period of performance must be clearly defined in the project SOW and will be finalized during award negotiations. The PI will be required to present an update on progress toward accomplishing research milestones and goals of the project at an annual Milestone Meeting to be held in the National Capital Region. Annual Milestone Meetings will be held at the conclusion of Year 1 and every subsequent year in the period of performance and will be attended by members of the GWIRP Programmatic Panel, CDMRP staff, and the USAMRAA Grants Officer.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.
For this award mechanism, direct costs may be requested for (not all-inclusive):

- Transportation
- Lodging
- Participation incentives

May be requested for travel including:

- Travel costs for the PI to attend annual Milestone Meetings in the National Capital Region. Costs associated with travel to these meetings should be included in Years 1, 2, 3, and 4 of the budget. These travel costs are in addition to those allowed for annual scientific/technical meetings.

- Travel in support of multidisciplinary collaborations.

- Travel costs for up to three investigators to travel to one scientific/technical meeting per year to present project information or disseminate project results, in addition to the required Milestone Meetings described above.

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:
• **Impact**

  o To what degree the proposed research could lead to a solution for the [FY21 GWIRP Overarching Challenge](#) of eliminating the health consequences associated with GWI and/or revolutionizing treatment.

  o If the project addresses another [FY21 GWIRP Overarching Challenge(s)](#), how well the proposed research addresses the challenge. If the project addresses an applicant-defined overarching challenge, to what degree application provides adequate justification within the context of [The Gulf War Illness Landscape](#).

  o To what degree the anticipated short-term outcomes of the proposed clinical trial will benefit Veterans with GWI.

  o To what degree the proposed clinical trial will have long-term benefits for Veterans with GWI and how well the long-range vision describes implementation of the intervention in the clinic.

  o To what degree the proposed intervention represents an approach that is fundamentally better than interventions already approved or in clinical development.

• **Research Strategy and Feasibility**

  o How well the scientific rationale is supported by previous pilot trials in GWI Veterans or by outcomes from other conditions related to GWI.

  o Whether the application includes plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project.

  o To what degree the application provides preliminary data collected from previous pilot trials and the extent to which the application describes how this study will validate or confirm those findings.

  o How well the application describes objective biomarkers to be used as clinical endpoints. The degree to which biomarkers originate from the investigator’s laboratory or are derived from previously published markers in the context of GWI.

  o Whether the type of late-stage clinical trial proposed (e.g., single group, parallel, crossover) is appropriate to meet the project’s objectives.

  o How well the study groups, data collection and management procedures, and analyses are designed to clearly answer the clinical objective.

  o Whether use of both the CDC and Kansas GWI case definitions is described. If any additional case definitions are proposed, including any targeted subgroups, how well they are described and justified.

  o How well potential problem areas and alternative methods/approaches are discussed.
• **Intervention**
  
  o How well the intervention to be tested is identified and described.

  o Whether there is evidence of availability of the therapeutic from its source for the duration of the proposed clinical trial.

  o To what degree the application has provided preclinical pharmacological findings, dosage studies, and other clinical studies that examine the safety and stability of the intervention.

  o How well the study procedures, including interaction with the human subject, are described.

  o Whether the Clinical Monitoring Plan sufficiently describes the types of monitoring visits, intervals (based on level of risk), and how corrective actions will be reported.

• **Regulatory Strategy and Transition Plan**

  o How the regulatory strategy and development plan to support the product indication or product label change, if applicable, are appropriate and well described.

  o Whether the application includes documentation that the study is exempt from FDA regulation, or that the IND or IDE application has been submitted to the FDA, as appropriate.

  o How well the documentation provided supports the feasibility of acquiring an active IND or IDE covering the proposed trial, if applicable.

  o For investigator-sponsored regulatory exemptions (e.g., IND, IDE), whether there is evidence of appropriate institutional support, including capabilities to ensure monitoring as required by the FDA.

  o Whether plans to comply with GMP, GLP, and GCP guidelines are appropriate.

  o Whether the identified next level of development and/or commercialization is realistic.

  o Whether the funding strategy described to bring the intervention to the next level of development (e.g., specific industry partners, specific funding opportunities to be applied for) is reasonable and achievable.

  o Whether the schedule and milestones for bringing the intervention to the next level of development (next-phase clinical trials, transition to industry, delivery to the market, incorporation into standard practice, and/or approval by the FDA) are achievable.

  o If applicable, whether the risk analysis for cost, schedule, manufacturability, and sustainability is realistic and reasonable.

  o How well the application identifies intellectual property ownership and subsequent government access to products or technologies supported by this program announcement.
• **Recruitment, Accrual, and Feasibility**
  
  o Whether the application has demonstrated access to the proposed 1990-1991 Gulf War Veteran population.

  o How well the inclusion/exclusion criteria considers the specific risk profile and the standard of care for the patient population and whether justification for limiting inclusion is provided.

  o Whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.

  o How well the application describes outreach and recruitment activities and includes the involvement of appropriate sources within the community and considerations for Veteran subject compensation.

  o How well the application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.

• **Statistical Model and Data Analysis Plan**
  
  o To what degree the statistical model and data analysis plan are suitable for the planned study.

  o Whether a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study is provided.

  o The extent to which methods used for data collection (data capture, verification, disposition, and data reporting) are feasible.

  o How well measures taken to protect the privacy of human subjects and maintain confidentiality of study data are addressed.

  o The extent to which laboratory evaluations are described and will be used to meet the objectives of the study.

• **Ethical Considerations**
  
  o Whether the population selected to participate in the trial stands to benefit from the knowledge gained.

  o Whether the level of risk to human subjects is minimized and how the safety monitoring and reporting plan is appropriate for the level of risk.

  o Whether a research monitor with expertise consistent with the nature of the potential risk(s) is identified.

  o To what degree the processes for seeking informed consent are appropriate.
• **Personnel and Communication**
  
  o Whether the composition of the study team (e.g., study coordinator, statistician) is appropriate.
  
  o To what degree the study team’s background and expertise are appropriate to accomplish the proposed work (e.g., expertise in GWI, statistical expertise, expertise in conducting clinical trials, and FDA experience, if applicable).
  
  o How appropriate the study team members’ levels of effort are to ensuring successful completion of the proposed trial.

• **Biorepository Contribution Statement** *(Biorepository Contribution Option only)*
  
  o How well the types of datasets and/or biospecimens to be contributed to the BBRAIN are described.
  
  o To what extent the application describes any special preparation, facilities and/or technical capabilities necessary for collection, storage, and transfer of data and specimens to BBRAIN.
  
  o How well technical capabilities necessary for collection, storage, and transfer of data and/or Gulf War Veteran specimens to BBRAIN are described.
  
  o Whether plans for adherence to the SOPs, quality assurance measures, and annotation standards for clinical and pathological specimens and data established by the BBRAIN members are adequately detailed.
  
  o How well the application describes plans to coordinate with the BBRAIN for the resolution of any intellectual and material property issues related to contribution of samples and/or data.
  
  o How well the application addresses the informed consent processes and how patient data confidentiality will be maintained in compliance with federal and state regulations, if applicable.

• **Clinical Consortium Collaboration Statement** *(Clinical Consortium Collaboration Option only)*
  
  o How well the PI’s experience in conducting multi-institutional clinical trials demonstrates willingness and ability to participate in collaborative clinical trials and function in the Consortium.
  
  o How well the application describes the extent to which the existing GWICTIC infrastructure will be leveraged and integrated into the clinical trial, including interaction of a named Clinical Research Coordinator.
o How well the application describes commitment to adhere to the SOPs, quality assurance measures, clinical protocols, CDEs, and data management procedures of the GWICTIC.

o How well a letter of collaboration from the GWICTIC demonstrates endorsement of the clinical trial.

In addition, the following **unscored** criteria will also contribute to the overall evaluation of the application:

- **Environment**
  
o To what degree the scientific environment, clinical setting, and the accessibility of institutional resources support the clinical trial at each participating center or institution (including collaborative arrangements).
  
o Whether there is evidence for appropriate institutional commitment from each participating institution.
  
o If applicable, to what degree the intellectual and material property plan is appropriate for the proposed clinical trial.

- **Budget**
  
o Whether the direct costs exceed the allowable direct costs as published in the program announcement.
  
o Whether the budget is both adequately justified and appropriate for the proposed research.
  
o If applicable, the extent the proposed costs for contribution of samples and/or data to BBRAIN are appropriate.
  
o If applicable, the extent the accounting of proposed costs for collaboration with the GWICTIC are appropriate.

- **Application Presentation**
  
  - To what extent the writing, clarity, and presentation of the application components influence the review.

**II.E.1.b. Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:
• Ratings and evaluations of the peer reviewers

• Relevance to the mission of the DHP and FY21 GWIRP, as evidenced by the following:
  ○ Adherence to the intent of the award mechanism
  ○ Program portfolio composition
  ○ Relative clinical impact
  ○ Relative outcomes from the PI’s previous GWI-related research (if applicable)

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC, on behalf of the DHA and the OASD(HA). The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.army.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the GWIRP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.88, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).
An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DODGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY21 funds are anticipated to be made no later than September 30, 2022. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

Pre-Award Costs: An institution of higher education, hospital, or other non-profit organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document.

Federal Government Organizations: Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.
II.F.1.a. PI Changes and Award Transfers

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

Unless otherwise restricted, changes in PI will be allowed at the discretion of the Grants Officer, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DODGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D General Terms and Conditions; the USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations; Addendum to the DoD R&D General Terms and Conditions; and the USAMRAA General Research Terms and Conditions with For-Profit Organizations for further information.

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. **If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.**

Annual progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section.
The Award Expiration Transition Plan must outline if and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Inclusion Enrollment Reporting Requirement: Enrollment on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this program announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. Recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

    Phone:  301-682-5507
    Email:  help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

    Phone:  800-518-4726; International 1-606-545-5035
    Email:  support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 601a. The program announcement numeric version code will match the General Application Instructions version code 601.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Intervention (Attachment 5) is missing.
- Human Subject Recruitment and Safety Procedures (Attachment 6) is missing.
- Data Management (Attachment 7) is missing.
- Regulatory Strategy (Attachment 8) is missing.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:
• An FY21 GWIRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY21 GWIRP Programmatic Panel members can be found at https://cdmrp.army.mil/gwirp/panels/panels21.

• The application fails to conform to this program announcement description.

• Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

• To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY21, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.

• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

• Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.

• Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• The proposed research is not a clinical trial.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• The invited application does not propose the same research project described in the pre-application.

• For studies requiring an IND or IDE, documentation of IND/IDE submission and/or active status is not provided.

• The proposed project includes preclinical research.

• The application describes research focusing on ALS.

• The PI does not meet the eligibility criteria.
The application describes research whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI.

**II.H.2.d. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
### II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance (extramural submissions only)</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)</td>
<td>Complete tabs as instructed</td>
<td></td>
</tr>
<tr>
<td>Attachments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstracts: Upload as Attachment 3 with file name “Abstracts.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 4 with file name “SOW.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention: Upload as Attachment 5 with file name “Intervention.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name “HumSubProc.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 7 with file name “Data_Manage.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory Strategy: Upload as Attachment 8 with the file name “Regulatory.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Personnel and Organization: Upload as Attachment 9 with file name “Personnel.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveys, Questionnaires, and Other Data Collection Instruments: Upload as Attachment 10 with file name “Surveys.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 11 with file name “Transition.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 12 with file name “Impact.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Option Statements: Upload as Attachment 13 with file name “Options.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 14 with file name “RequiredReps.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suggested DOD Collaborating Military Facility Budget Format: Upload as Attachment 15 with file name “MFBudget.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Personal Data</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Budget (intramural submissions only)</td>
<td>Suggested DOD Military Budget Format, including justification</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
</tbody>
</table>
**APPENDIX 1: ACRONYM LIST**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
</tr>
<tr>
<td>ALS</td>
<td>Amyotrophic Lateral Sclerosis</td>
</tr>
<tr>
<td>BBRAIN</td>
<td>Boston Biorepository, Recruitment, and Integrative Network</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CDE</td>
<td>Common Data Element</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DODGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FAA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practice</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>GWI</td>
<td>Gulf War Illness</td>
</tr>
<tr>
<td>GWICTIC</td>
<td>Gulf War Illness Clinical Trials and Interventions Consortium</td>
</tr>
<tr>
<td>GWIRP</td>
<td>Gulf War Illness Research Program</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
</tr>
<tr>
<td>ICH E6</td>
<td>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exemption</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IOM</td>
<td>Institute of Medicine (now, National Academy of Medicine)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LAR</td>
<td>Legally Authorized Representative</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>OASD(HA)</td>
<td>Office of the Assistant Secretary of Defense for Health Affairs</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RDT&amp;E</td>
<td>Research, Development, Test, and Evaluation</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOPs</td>
<td>Standard Operating Procedures</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>STEM</td>
<td>Science, Technology, Engineering, and/or Mathematics</td>
</tr>
<tr>
<td>UEI</td>
<td>Unique Entity Identifier</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>Department of Veterans Affairs</td>
</tr>
</tbody>
</table>